Needham & Company Raises Price Target on Rogers (ROG) to $75 Following Solid 3Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Needham & Company Raises Price Target on Rogers (ROG) to $75 Following Solid 3Q
November 2, 2016 5:45 PM EDT
Rogers (NYSE: ROG) reported Q3 EPS of $0.88, $0.20 better than the analyst estimate of $0.68. Revenue for the quarter came in at $165.3 million versus the consensus estimate of $154.02 million.
For earnings history and earnings-related data on Rogers (ROG) click here.
...
More
November 2, 2016 6:27 AM EDT
Genentech, a member of the Roche Group (OTC: RHHBY) announced that new data from Actemra (tocilizumab) and Rituxan (rituximab) will be presented during the 2016 American College of Rheumatology (ACR) and Association for Rheumatology Health Professionals (ARHP) Annual Meeting, November 11-16, Washington, D.C. These data add to the significant body of evidence for Actemra and Rituxan in RA and other serious immune-mediated conditions including GCA, systemic sclerosis (SSc), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
Advances in our scientific understanding behind immune pathways are guiding the development of potential new treatments for severe... More
